Journal of Oncology Pharmacy Practice最新文献

{"title":"Chemotherapy Orders Team: A non-traditional operational and clinical support team enhancing order set development and implementation.","authors":"Thomas J Vassas, Emily Fenner, Vishnuprabha Vogel","doi":"10.1177/10781552251369434","DOIUrl":"10.1177/10781552251369434","url":null,"abstract":"<p><p>ObjectiveOncology treatment regimens require increasing information technology (IT) integration in health systems to enhance delivery and safety, however, this creates a burden on medical teams and clinical pharmacists to manage. This primer introduces the University of Michigan Health Academic Medical Center's (UMH-AMC) response to this need with the Chemotherapy Orders Team (COT).SummaryThe COT includes five clinical oncology pharmacy generalists with a split full-time equivalent (FTE) appointment in COT-based activities and staffing in infusion. They manage the clinical content of oncology and non-oncology treatment and therapy plans at UMH-AMC, including over 1330 commercial plans and over 260 investigational plans. The COT ensure compliance with national and regulatory guidelines for order sets. This involves leaning on order group standardization to improve the efficiency of treatments across multiple disease states. The COT has been instrumental in managing the compounding standards for all infusion agents, including support to the electronic health record (EHR) team.ConclusionThe COT is an innovative team of clinical pharmacist infusion generalists, providing non-traditional clinical and operations support. They work alongside medical teams, pharmacy operations, and health informatics to provide robust management of EHR pathways for oncology and non-oncology related therapies. Importantly, they act as a translational liaison between the clinical teams and the EHR. Their efforts to modernize and improve the treatment and therapy plan experience at UMH-AMC has been an ongoing exercise, with many improvements in order set standardization and communication.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251369434"},"PeriodicalIF":0.9,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk-based analytical quality control of chemotherapy preparations: A simulation and FMECA approach.","authors":"Soumaya El Baraka, Oualid Ziraoui, Zineb Lachhab, Omar El Hamdaoui, Said Zouhair","doi":"10.1177/10781552251374565","DOIUrl":"10.1177/10781552251374565","url":null,"abstract":"<p><p>IntroductionEnsuring the analytical quality control of chemotherapy preparations is essential to patient safety and treatment efficacy. However, the risk of preparation errors remains a critical concern in hospital pharmacy. Failure Mode, Effects, and Criticality Analysis (FMECA) is a structured risk assessment tool that can help identify, evaluate, and mitigate potential failures. This study integrates FMECA within a simulation-based training approach to enhance the safety and reliability of chemotherapy preparation quality control.Materials and MethodsA simulation-based learning program was implemented at the Faculty of Medicine and Pharmacy of Marrakech. Pharmacy students performed quality control steps, including limpidity testing, sterility testing, dosage uniformity, content verification, ingredient identification, and labeling accuracy. Analytical techniques such as UV-visible spectrophotometry, microbiological culture, and barcode verification were used. FMECA was applied at each critical step to assess failure risks. Statistical analysis measured pre- and post-training performance improvements.Results and DiscussionSimulation-based training significantly improved quality control performance across all parameters (p < 0.05). Notably, labeling errors decreased (p = 0.005), sterility compliance improved (p = 0.02), and dosage accuracy increased (p = 0.01). FMECA identified high-risk failure modes, reinforcing the need for standardized protocols and advanced analytical techniques.ConclusionIntegrating FMECA with simulation-based training enhances analytical quality control, reduces human errors, and strengthens adherence to Good Preparation Practices (GPP). These findings highlight the importance of proactive risk management in hospital pharmacy.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251374565"},"PeriodicalIF":0.9,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond the budget impact model: A case study for glucarpidase and the real cost of managing curable toxicities.","authors":"Setareh A Williams, Rich J Weiss","doi":"10.1177/10781552251374598","DOIUrl":"10.1177/10781552251374598","url":null,"abstract":"<p><p>The greatest challenge in healthcare today lies in managing limited resources to deliver high-quality care to the patients who need it the most. Payers heavily rely on budget impact models to assess the net costs or potential savings associated with adding a new intervention and to inform their formulary decision. Drugs developed for rare conditions are often prohibitively expensive due to the complex manufacturing processes and investments required to undertake clinical trials. These interventions often play a critical role in organ preservation and can be lifesaving when no alternative therapies are available. The significant cost of these treatments has to be weighed against the potential cost consequences of not using the treatment including downstream complications of an avoidable event. Over the past few decades, oncologic treatments have seen significant advancements. Despite these innovations, radiation therapy and chemotherapy remain the backbone of treatment for many types of cancers. These therapies often damage healthy cells alongside cancer cells, leading to a range of side effects that can affect multiple organ systems. While some side effects, such as those from radiation therapy, may be resolved within weeks or months after treatment ends, others may persist or emerge months to years later. Worse yet is the impact of these side effects on patients' ability to continue with their cancer treatment regimen. Here we discuss a case of glucarpidase in managing high dose methotrexate toxicity and consideration of full impact, not only on the budget but also the patient.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251374598"},"PeriodicalIF":0.9,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety outcomes of teclistamab accelerated dose escalation.","authors":"Yumena Kawasaki, Aaron Paul Steele, Aaron Rosenberg, Julie Guglielmo","doi":"10.1177/10781552241268429","DOIUrl":"10.1177/10781552241268429","url":null,"abstract":"<p><p>IntroductionTeclistamab, a bispecific T-cell engaging antibody targeting B-cell maturation antigen (BCMA), is indicated for the treatment of relapsed or refractory multiple myeloma after at least four lines of therapy. It has boxed warnings for life threatening cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). To mitigate these risks, teclistamab is initiated using step-up doses. This article examines safety event rates following the implementation of a 2-day separation between step-up doses at one institution to streamline patient care.MethodsThis was a retrospective, single-center study encompassing all patients who received teclistamab within a 1-year period. The primary endpoint was the overall incidence of CRS and ICANS. Secondary endpoints included hospital length of stay, hematological toxicities, infection rates, among other adverse events.ResultsA total of 27 patients were included in the analysis and stratified into accelerated (days 1,3,5) or standard (days 1,4,7) dosing groups. CRS occurred in 48% (11) of patients for the accelerated dosing and 50% (2) for the standard dosing group. ICANS was seen in 17% (4) of patients in the accelerated dosing group and none in the standard dosing group. Average length of stay in the accelerated dose was 7.6 days versus 9.2 days in the standard dose group.ConclusionAccelerated dose escalation of teclistamab yielded safety event rates comparable to those in the literature. These findings may support outpatient administration for teclistamab. Accelerated dose escalation strategy allowed for the optimization of hospitalization and resources.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"977-982"},"PeriodicalIF":0.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12290224/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141875147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ribociclib-Induced hepatotoxicity exacerbated by fenugreek supplement use: A case report.","authors":"Yousra Al Harrak, Sihame Lkhoyaali, Oumaima Lamsyah, Marie Monique Tine, Hafsa Bechar, Ghita Benabdallah, Houda Sefiani, Saber Boutayeb, Hassan Errihani","doi":"10.1177/10781552251340911","DOIUrl":"10.1177/10781552251340911","url":null,"abstract":"<p><p>BackgroundCyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, such as ribociclib, are the cornerstone of treatment for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. However, ribociclib is known to cause hepatotoxicity, and the role of other dietary supplements in this process is not well understood.Case PresentationA 47-year-old woman with metastatic breast cancer experienced grade III hepatotoxicity shortly after starting ribociclib. Despite discontinuing the drug, transaminase levels remained elevated. Using the the Roussel Uclaf Causality Assessment Method (RUCAM), a probable drug-induced liver injury was identified (score: 6). Upon disclosure of concurrent use of a fenugreek-based supplement, the revised RUCAM score dropped to 4. Further anamnesis revealed concurrent intake of a fenugreek-based supplement, prompting a revised RUCAM score of 4. The Naranjo Adverse Drug Reaction Probability Scale also indicated a <i>possible</i> association (score: 4). In contrast, the Drug Interaction Probability Scale (DIPS) scored 5, suggesting a <i>probable</i> herb-drug interaction between ribociclib and fenugreek.Management and OutcomeTransaminase levels gradually returned to normal within eight weeks of stopping ribociclib and four weeks after discontinuing the fenugreek supplement. The patient was counseled to avoid herbal supplements and initiated on palbociclib as an alternative CDK4/6 inhibitor. Liver function remained stable with no recurrent hepatotoxicity.DiscussionFenugreek modulates CYP3A4, which metabolizes ribociclib. This case highlights underrecognized herb-drug interactions in oncology.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1018-1023"},"PeriodicalIF":0.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144102041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determinants of clinic absenteeism in a chemotherapy service of a cancer center located at Rio de Janeiro, Brazil.","authors":"Amanda Oliveira Serra-Campos, Filipe Dos Santos Soares, Elizangela Domiciano Garcia Barreto, Erika da Silva Magliano","doi":"10.1177/10781552241264288","DOIUrl":"10.1177/10781552241264288","url":null,"abstract":"<p><p>IntroductionClinic absenteeism promotes higher waiting lists for medical procedures and public resources waste.ObjectivesThe present work aimed to identify the reasons for clinic absenteeism from each cycle of the antineoplastic chemotherapy treatment, as well as to determine the socio-demographic, clinical and treatment profiles of this population.MethodsThis observational prospective work evaluated pediatric and adult patients which missed their chemotherapy cycle between May and October 2023 in a Cancer Center located in Rio de Janeiro, Brazil. Clinic absenteeism rate was calculated, and socio-demographic profile was described. Reasons for absenteeism, treatment protocol and most used drugs were also identified.ResultsThis work analyzed data from 69 patients, the majority above 60 years old. Approximately 60% were male, 33.3% had little to no education and 63.8% lived outside the center city. Absenteeism average monthly rate was 1.73% for adults and 0.87% for children. The most related non-attendance reasons were patient feeling too ill to attend their chemotherapy session, failure to remember the cycle day and lack of means of transportation. Most prevalent neoplasms were from the digestive tract (46%). Fluorouracil, irinotecan, oxaliplatin and gemcitabine were the most discarded drugs due to absenteeism.ConclusionsOlder patients and the ones residing far away from the Center tend to miss the scheduled chemotherapy cycles. However, most reasons for absenteeism could be avoided by confirmation calls or text messages. These procedures implementation could lead to a lower absenteeism rate and less resource waste.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"871-877"},"PeriodicalIF":0.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141752014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and oncological effectiveness after desensitization in patients with previous hypersensitivity reactions to chemotherapy.","authors":"Rosalaura V Villarreal-González, Oscar Vidal-Gutiérrez, Javier A Martínez-Moyano, Marianela Madrazo-Morales, Kathia S Sáenz-Cantú, Diana E Cadenas-García, Victor M Oyervides-Juárez, María Fernanda Noriega-Iriondo, Patricia Rodríguez-Niño","doi":"10.1177/10781552241269766","DOIUrl":"10.1177/10781552241269766","url":null,"abstract":"<p><p>IntroductionTaxanes and platinum are first-line treatments in gynecological tumors with high rates of hypersensitivity reactions (HSRs), leading to discontinuation of treatment. Desensitization involves induction of temporary tolerance to previously sensitized medications. The aims of this study are to describe HSRs to paclitaxel and carboplatin and evaluate the safety and effectiveness of desensitization protocols in gynecological cancer patients.MethodsOriginal, retrospective, descriptive, analytical study, approved by Bioethics and Research Committee, included >18-year-old patients with gynecological tumors experiencing HSRs to first-line chemotherapy. Patients underwent 3-bag-12-step desensitization.Results174 desensitization (95 paclitaxel, 79 carboplatin) in 33 female patients, mean age 45.5 years (18-71y). Cancer diagnosis: breast 8 (24.2%), ovarian 14 (42.2%), endometrial 2 (6.1%) and cervix 9 (27.2%). HSR occurred in paclitaxel during cycles 1-2 and in carboplatin after 6 cycles. The most frequently seen HSR symptom was cardiovascular with paclitaxel (94.7%), and cutaneous (93.3%) with carboplatin. Three-bags 12-steps desensitization protocol (initial dilution 1:100) in 5.67hrs. All patients reached total dose desensitization: 82% with no reaction, 12% mild, 6% moderate and 0% severe reaction. Mean disease-free interval and progression-free interval in months (m): breast cancer 29 m and 14 m, ovarian 22 m and 9 m, endometrial 40 m and cervical cancer: 67.5 m and 27 m. Twenty-five patients (73.5%) are still alive.ConclusionHSRs to paclitaxel manifest in the first 1-2 cycles and to carboplatin after 6 cycles. Symptoms include cardiovascular, atypical neuromuscular and urticaria. Changing treatment lines impacts prognosis. Our study revealed that ovarian cancer patients undergoing desensitization protocols achieved longer progression-free intervals. All patients successfully reached total dose desensitization. This study provides evidence of the effectiveness and safety of desensitization and promising perspective for continuing first-line treatment with HSRs.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"955-964"},"PeriodicalIF":0.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142086123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BRAF inhibitors with or without MEK inhibitors in advanced BRAF-positive non-small cell lung cancer: A systematic review.","authors":"Animesh Saha, T Raja, Amit Dutt Dwary, Indranil Ghosh, Prabrajya Narayan Mahapatra, Tanmoy Mukhopadhay","doi":"10.1177/10781552251322452","DOIUrl":"10.1177/10781552251322452","url":null,"abstract":"<p><p>ObjectiveAbout 1% to 5% of cases of non-small cell lung cancer (NSCLC) have been found to have a BRAF mutation. There is no phase III data, despite the fact that numerous phase II and retrospective studies have demonstrated the efficacy of single agent BRAF inhibition and combination BRAF/MEK inhibition in patient groups that have received treatment and those who have not. Our goal in this systematic review was to provide an overview of the available evidence in this context.Data SourcesA thorough search was conducted in the PubMed, Medline, Embase, and Cochrane databases for English-language papers published between January 2000 and December 2023 that had full text accessibility. Independently, one author screened the eligible studies that fit our predetermined requirements. A synthesis of the qualitative data was conducted, and the design and quality of the studies were evaluated.Data SummaryThere were 2952 articles found using the search method. Twelve publications with a total of 753 patients were included after two rounds of screening. 33-75% was the objective response rate (ORR). 64-100% was the disease control rate (DCR). The time span for the answer varied from 6.4 to 16.7 months. The range of the median progression-free survival (PFS) was 1.2 to 17.5 months. The range of the median overall survival (OS) was 1.7-25.5 months. When comparing studies with single agent BRAF inhibitors to those reporting the results of BRAF plus MEK inhibitors, the response rates, duration of response, and survival were better in the former case. When untreated patients receiving BRAF/MEK inhibitor therapy were compared to previously treated patients, the results were also improved. Hypertension, pyrexia, hyponatremia, neutropenia, dyspnoea, anaemia, abnormal liver function, asthenia, and cutaneous epidermoid carcinoma were among the frequently reported grade ≥3 toxicity.ConclusionsPatients with advanced NSCLC that include a BRAF mutation have demonstrated encouraging clinical outcomes with a manageable safety profile when treated with BRAF inhibitors, either in combination with or without MEK inhibitor therapy. In patients who had not received treatment before, combination treatment produced greater results.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"991-999"},"PeriodicalIF":0.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comprehensive study of adverse effects of chemotherapy on female breast cancer patients in NORI Cancer Hospital, Islamabad in a developing country.","authors":"Abdullah, Areesha Abid, Humza Saeed, Zabeehullah, Uswa Iftikhar, Muhammad Khubaib Arshad, Muhammad Uzair Shahid, Tayyab Rasool, Faizan Fazal, Aman Goyal, Anum Akbar","doi":"10.1177/10781552241266254","DOIUrl":"10.1177/10781552241266254","url":null,"abstract":"<p><p>IntroductionBreast cancer is one of the top three malignancies worldwide. While radiotherapy, hormone replacement therapys, and chemotherapy are treatments, chemotherapy causes adverse effects that hinder daily life activities.ObjectivesTo assess the prevalence, severity, and association of symptomatic toxicities in female breast cancer patients affecting various organ systems post systemic chemotherapy (adjuvant and neoadjuvant), and their impact on daily activities. Additionally, to determine the severity of adverse effects in specific age groups and their association with family history and disease stage.MethodologyAn observational study was conducted on 253 female breast cancer patients receiving chemotherapy at NORI Cancer Hospital from May to October 2023. Data collection tools included the NCI-PRO-CTCAE standardized questionnaire and patient medical records. Analysis was performed using descriptive statistics, T-tests, and Chi-square tests.ResultsAmong the 253 patients, 41.4% were aged 41-50. Significant weight changes (<i>p</i> = 0.034) were observed with more than three chemotherapy cycles. Notable associations included increased chemotherapy cycles with gastrointestinal (mouth/throat sores <i>p</i> = 0.031, vomiting <i>p</i> = 0.021), respiratory (cough <i>p</i> = 0.04), cardiovascular (arm/leg swelling <i>p</i> = 0.007, palpitations <i>p</i> = 0.052), integumentary (hair loss <i>p</i> = 0.000, skin dryness <i>p</i> = 0.054), and musculoskeletal (fatigue <i>p</i> = 0.002) adverse effects. Positive family history and the 18-30 age group also showed significant associations with adverse effect severity. Disease stage significantly influenced the nervous system (stage 2 <i>p</i> = 0.007, stage 3 <i>p</i> = 0.01).ConclusionThe severity of adverse effects varies among age groups, depending on disease stage, genetics, and treatment duration. These patient-reported outcomes highlight the need for better management strategies considering prognostic factors and treatment adverse effects.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"939-948"},"PeriodicalIF":0.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141875125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Equity, diversity, and inclusion in oncology pharmacy practice: Everyone's business.","authors":"Pascale Dettwiller, Suhani Ghiya, Jurga McLean, Stewart O'Callaghan, AdeDolapo Sanni, Nisha Shaunak, Lilia So, Steve Williamson, Shereen Nabhani-Gebara","doi":"10.1177/10781552241264717","DOIUrl":"10.1177/10781552241264717","url":null,"abstract":"<p><p>IntroductionEquity, Diversity, and Inclusion (EDI) is gaining increased attention within all industries healthcare being no exception. The terminology Equity, Diversity, and Inclusion and its abbreviation EDI gained popularity in the early 2000's when varied socio-political factors prompted many organisations to examine EDI concepts and how to operationalise them. The growing diversity of our society requires cross-cultural inclusive approaches to increase equity and access to services.MethodThis unique research is community-led research supported by the British Oncology Pharmacy Association, in which the members of the BOPA community are equal partners to inform action on policies that address EDI. This research was a cross-sectional study involving an online survey of financial BOPA members.ResultsDemographic data was extracted, and the quotes were analysed for common themes. The majority of respondents were women, and the largest age group was between 34 and 44. The first cause of microaggressions identified by the respondents was of racial and ethnic origin, followed by marital status and religious nature. Participants described the lack of diversity in senior positions and the microaggressions experienced by those who hold leadership positions. Some participants described how some situations at work made them feel excluded or alienated. The impact of discrimination and bullying/microaggressions extended to patients was also reported.ConclusionDespite strategic directions encompassing this aspect, this research underscores the pressing need for more evidence on the lack of EDI in healthcare institutions. Our findings, located in the pharmacy oncology specialty, have identified the problem and highlighted the potential benefits of addressing it. More needs to be done in training and professional development to address unconscious bias and change behaviours.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"878-886"},"PeriodicalIF":0.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12290223/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141752016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}